Imagyn Medical Technologies, Inc. Completes Purchase of International Isotopes' Brachytherapy Seed Manufacturing Assets

Apr 30, 2001, 01:00 ET from Imagyn Medical Technologies, Inc.

    IRVINE, Calif., April 30 /PRNewswire/ -- Imagyn Medical Technologies, Inc.
 announced today that they have completed the purchase from International
 Isotopes, Inc. of all assets related to the International Isotopes' Iodine
 125 brachytherapy seed manufacturing business.
     International Isotopes, Inc. had been manufacturing Imagyn's isostar(TM)
 at its Denton, Texas facility.  Imagyn will immediately assume responsibility
 for manufacturing the brachytherapy seeds at the same location in leased
 space.
     "We very excited that the acquisition has been completed," said Charles A.
 Laverty, Chairman and CEO of Imagyn.  "Imagyn now has control over its entire
 brachytherapy Business.  We will be able to totally integrate the marketing,
 manufacturing and distribution of our isostar(TM) Iodine 125 seed.  We have
 already developed and intend to implement improvements in the manufacturing
 process that will allow us to be more efficient and cost effective.  This
 should insure that our customers receive reliable, predictable and consistent
 service with the highest quality seed.  We are also committed to making Imagyn
 a leader in the development of new product offerings in this market.  The
 addition of the manufacturing capability also provides flexibility in research
 and development that will allow us to bring products to market in a more
 timely and economical manner."
 
     Imagyn Medical Technologies, Inc. is a designer, manufacturer and marketer
 of urological, gynecological and general surgery medical products to the
 health care market.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X18659231
 
 

SOURCE Imagyn Medical Technologies, Inc.
    IRVINE, Calif., April 30 /PRNewswire/ -- Imagyn Medical Technologies, Inc.
 announced today that they have completed the purchase from International
 Isotopes, Inc. of all assets related to the International Isotopes' Iodine
 125 brachytherapy seed manufacturing business.
     International Isotopes, Inc. had been manufacturing Imagyn's isostar(TM)
 at its Denton, Texas facility.  Imagyn will immediately assume responsibility
 for manufacturing the brachytherapy seeds at the same location in leased
 space.
     "We very excited that the acquisition has been completed," said Charles A.
 Laverty, Chairman and CEO of Imagyn.  "Imagyn now has control over its entire
 brachytherapy Business.  We will be able to totally integrate the marketing,
 manufacturing and distribution of our isostar(TM) Iodine 125 seed.  We have
 already developed and intend to implement improvements in the manufacturing
 process that will allow us to be more efficient and cost effective.  This
 should insure that our customers receive reliable, predictable and consistent
 service with the highest quality seed.  We are also committed to making Imagyn
 a leader in the development of new product offerings in this market.  The
 addition of the manufacturing capability also provides flexibility in research
 and development that will allow us to bring products to market in a more
 timely and economical manner."
 
     Imagyn Medical Technologies, Inc. is a designer, manufacturer and marketer
 of urological, gynecological and general surgery medical products to the
 health care market.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X18659231
 
 SOURCE  Imagyn Medical Technologies, Inc.